Apollo Health announced that BrainScan, an advanced blood test offered in collaboration with its partner Neurocode, can detect early-stage of dementia years before onset of symptoms.
BrainScan is designed to analyse three biomarkers to evaluate the risk of Alzheimer’s disease (AD) and other neurodegenerative conditions.
It has adequate sensitivity to replace invasive and expensive spinal taps or PET brain scans.
The three biomarkers include p-Tau 217, neurofilament light (NfL), and glial fibrillary acidic protein (GFAP).
p-Tau 217 is a biomarker of AD processes, and its test is sensitive to detect AD pathology when the patient is pre-symptomatic and is 95% accurate in predicting amyloid pathology.
NfL is a marker of neuronal damage, which can detect if there is a problem with your neurons from causes like vascular disease, head trauma, or any neurodegenerative process.
GFAP is an early biomarker for inflammation and repair in the brain.
Apollo Health said that BrainScan test is highly sensitive and the first p-Tau 217 test widely available for consumers and allows them to choose who to share their results with.
Neurocode is specialised in Alzheimer’s disease and brain health testing, has published more external and internal data than any other p-Tau 217 blood test on the market.
Its p-Tau 217 test approach has shown to be highly sensitive and accurate and provides earlier diagnosis and treatment.
Unlike with other tests, BrainScan customers will receive a detailed interpretative report that includes their risk of developing dementia.
If their results are out-of-range, customers are supported by a nationally certified health coach, who will personally reach out to review results and offer guidance on deciding the next action.
